NCT00539344View on ClinicalTrials.gov

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Recurrent or Progressive Malignant Glioma
Interventions
DRUG

ANG1005

IV infusion once every 21 days

Trial Locations (6)

10032

Irving Comprehensive Cancer Center, Columbia University Medical Center, New York

22908

University of Virginia Health System, Charlottesville

48202

Henry Ford Health System, Detroit

77030

University of Texas, MD Anderson Cancer Center, Houston

78229

UT Health Science Center at the Cancer Therapy and Research Center (CTRC), San Antonio

02115

Dana Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

Angiochem Inc
All Listed Sponsors
lead

Angiochem Inc

INDUSTRY

NCT00539344 - A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma | Biotech Hunter | Biotech Hunter